Table 1

A summary of demographic characteristics

Patient no.	Eye	RPE tear grade	Age	BCVA (LogMAR) at first visit	BCVA (LogMAR) at last visit	Therapy prior to RPE tear (no.)	Time after RPE tears (d)	Total follow-up time (d)	FAF in RPE denuded area	HRDs	Subretinal mass at last follow-up
1	OS	2	86	0.35	1.4	Bevacizumab (1)	1938	2092	Dark	No	Yes
2	OD	3	74	0.48	1.5	Bevacizumab (1)	1681	1861	Hazy hyperfluorescent	Yes	No
3	OS	3	90	1.30	1.05	None	882	1911	Dark, patchy hyperfluorescent on the border	No	Yes
4	OD	3	77	0.4	0.7	Bevacizumab (4)	325	329	Dark	Yes	Yes
5	OS	4	80	0.7	1.3	Ranibizumab (3)	330	425	Dark	No	No
6	OD	3	76	1.3	NA	None	222	1455	Dark	Yes	Yes
7	OS	4	73	0.45	1.4	None	212	215	Dark	Yes	No
8	OD	2	70	0.15	0.1	None	1041	1344	Dark	Yes	No
9	OD	3	72	0.45	0.5	None	372	1302	Dark	Yes	Yes
	OS	4		0.5	0.7	Ranibizumab (3), Bevacizumab (1)	226	1302	Patchy hyperfluorescent	Yes	No
10	OD	1	82	0.7	1.5	Ranibizumab (3)	732	1671	Dark	Yes	Yes
11	OD	2	65	0.3	1.5	Ranibizumab (2)	52	168	Dark	Yes	No
12	OD	3	85	0.56	NA	None	53	54	Dark	Yes	No
	OS	4		0.2	NA	None	NA	54	Dark	Yes	No
13	OS	2	80	0.55	0.58	Ranibizumab (3)	111	455	Dark	No	No
14	OD	4	75	0.6	0.2	None	1165	3405	Patchy hyperfluorescent	Yes	No
15	OD	4	78	0.45	NA	Ranibizumab (2)	NA	NA	Dark	Yes	Yes
16	OS	3	86	1	1	None	128	337	Dark	Yes	Yes
17	OD	2	68	0.4	0.4	None	104	1701	Dark	Yes	Yes
18	OS	2	62	0.3	0.3	None	109	946	Patchy hyperfluorescent	Yes	Yes
19	OD	3	81	1.30	1.7	Ranibizumab (3)	333	1262	Dark	Yes	No
20	OD	4	83	1.3	NA	rtPA+SF6 (1), ranibizumab (1)	NA	819	Dark	No	No
21	OD	1	79	0.60	0.1	rtPA+SF6+bevacizumab (2)	670	925	Dark	Yes	Yes
22	OD	4	81	0.7	1.5	None	593	1648	Dark	Yes	No
	OS	4		0.26	1.3	Ranibizumab (1)	32	1648	Dark	Yes	No
23	OD	2	72	1	1.4	Ranibizumab (3)	77	231	Dark	No	No
24	OS	3	91	0.6	1.3	Ranibizumab (3)	895	992	Dark	Yes	No
25	OS	4	85	0.6	NA	Ranibizumab (2)	NA	NA	Dark	Yes	Yes
26	OD	1	71	0.6	0.6	None	110	2438	Patchy hyperfluorescent	Yes	No
27	OS	1	83	0.8	1	None	663	896	Dark	Yes	Yes
28	OD	4	61	0.3	0.4	None	317	709	Dark	Yes	Yes
29	OD	4	57	0.7	0.7	None	158	278	Patchy hyperfluorescent	Yes	No
30	OS	4	68	0.3	0.6	Ranibizumab (3)	1334	1996	Dark	Yes	No
31	OD	4	75	1.5	1.5	rtPA+SF6 (1), ranibizumab (5), bevacizumab (2)	NA	810	Dark	Yes	Yes
32	OD	1	67	1	NA	None	NA	NA	Dark	Yes	No
33	OD	4	72	0.2	NA	None	NA	NA	Dark	Yes	No

BCVA, best corrected visual acuity; d, days; FAF, fundus autofluorescence; HRDs, hyper-reflective dots; LogMAR, logarithm of the minimum angle of resolution; NA, not applicable; OD, the right eye; OS, the left eye; RPE, retinal pigment epithelium; rtPA, recombinant tissue plasminogen activator; SF6, sulphur hexafluoride 20%.